PubRank

Stefano Cereda

Author PubWeight™ 18.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. Int J Radiat Oncol Biol Phys 2013 2.04
2 Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009 1.82
3 Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc 2012 1.07
4 Adult Wilms' tumor: A monoinstitutional experience and a review of the literature. Cancer 2004 1.05
5 Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology 2006 0.87
6 Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer 2013 0.87
7 Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev 2012 0.86
8 Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumour Biol 2012 0.85
9 Adjuvant treatment in biliary tract cancer: to treat or not to treat? World J Gastroenterol 2012 0.83
10 Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer 2013 0.82
11 A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 2011 0.82
12 Amelanotic melanoma in a child with oculocutaneous albinism. Med Pediatr Oncol 2003 0.81
13 Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 2011 0.81
14 Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. Radiother Oncol 2013 0.80
15 Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. J Gastrointest Surg 2012 0.79
16 Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol 2012 0.79
17 An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs 2010 0.78
18 Rhabdomyosarcoma of the head and neck region: experience at the pediatric unit of the Istituto Nazionale Tumori, Milan. J Otolaryngol 2006 0.78
19 Role of taxanes in pancreatic cancer. World J Gastroenterol 2012 0.77
20 New therapies for pancreatic cancer: current standard. JOP 2007 0.75
21 Treatment trends in metastatic pancreatic cancer patients: Is it time to change? Dig Liver Dis 2010 0.75